Laura J Ruth, MD Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 841 E Placita De Arnoldo, Tucson, AZ 85718 Phone: 520-797-1891 Fax: 520-297-9765 |
David A Engelsberg, MD Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 6624 E Carondelet Drive, Tucson, AZ 85710 Phone: 520-886-8161 Fax: 520-885-9983 |
Dr. Todd L Locher, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2055 W Hospital Dr Ste 205, Tucson, AZ 85704 Phone: 520-575-6944 Fax: 520-575-1115 |
Dr. James Ferdinand Fiastro, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2055 W Hospital Dr Ste 175, Tucson, AZ 85704 Phone: 520-575-6944 Fax: 520-575-1115 |
Jerome Charles Rothbaum, M.D. Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 5240 E Knight Dr, Suite #114, Tucson, AZ 85712 Phone: 520-318-9681 Fax: 520-325-6774 |
News Archive
LDR, a privately held company with innovative spinal implants for both non-fusion and fusion applications, reached the critical 24-month follow-up phase for the one-level IDE study on its second generation Mobi-C® cervical artificial disc. LDR is the first and currently the only company to have completed enrollment for a concurrent one-level and two-level cervical artificial disc replacement study. LDR completed 1-Level enrollment in October 2007 and 2-Level enrollment in March 2008.
Researchers at Albert Einstein College of Medicine of Yeshiva University have found that overactivity of a brain enzyme may play a role in preventing weight gain and obesity.
Long-term exposure to air pollution has been linked to an increased risk of dying from COVID-19 and, for the first time, a study has estimated the proportion of deaths from the coronavirus that could be attributed to the exacerbating effects of air pollution for every country in the world.
Two consecutive nights of extended sleep, a typical weekend occurrence, appears to counteract the increased risk of diabetes associated with short-term sleep restriction during the work week, at least in lean, healthy, young men eating a controlled diet.
AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.
› Verified 6 days ago